纳米酶滴眼液用于视网膜屏障穿透和血管病变修复

IF 12.5 1区 综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES
Bai Xue, Shuyu Wang, Tingting Wu, Lulu Wang, Xuejiao J. Gao, Mengyuan Cao, Ming Tang, Yuxin Wan, Xiyun Yan, Wei Jiang, Bing Jiang
{"title":"纳米酶滴眼液用于视网膜屏障穿透和血管病变修复","authors":"Bai Xue,&nbsp;Shuyu Wang,&nbsp;Tingting Wu,&nbsp;Lulu Wang,&nbsp;Xuejiao J. Gao,&nbsp;Mengyuan Cao,&nbsp;Ming Tang,&nbsp;Yuxin Wan,&nbsp;Xiyun Yan,&nbsp;Wei Jiang,&nbsp;Bing Jiang","doi":"10.1126/sciadv.adu5571","DOIUrl":null,"url":null,"abstract":"<div >Retinal neovascularization diseases cause vision impairment due to abnormal blood vessel growth in the retina. Current treatments, including repeated intraocular anti–vascular endothelial growth factor injections, are invasive and often lead to discomfort and complicated hemorrhages. Here, we developed a noninvasive nanozyme eye drop capable of penetrating the fundus to eliminate reactive oxygen species (ROS) and thereby inhibit neovascularization. The nanozyme eye drops consist of liposomes formed by fluorinated and arginine–glycine–aspartic acid–modified phospholipids, which enhance the penetration of ocular barriers. The encapsulated superoxide dismutase–catalase cascade nanozyme within these liposomes allows for efficient ROS scavenging. In vitro and in vivo studies demonstrate that these nanozyme eye drops achieve deep retinal tissue penetration, alleviate oxidative stress, restore mitochondrial function, and suppress aberrant insulin-like growth factor binding protein 6 signaling, thereby inhibiting pathological neovascularization. Enhanced ocular bioavailability and minimal toxicity further underscore its promise as a safe and effective noninvasive treatment for retinal neovascularization diseases.</div>","PeriodicalId":21609,"journal":{"name":"Science Advances","volume":"11 38","pages":""},"PeriodicalIF":12.5000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.science.org/doi/reader/10.1126/sciadv.adu5571","citationCount":"0","resultStr":"{\"title\":\"Nanozyme eye drops for retinal barrier penetration and vasculopathy repair\",\"authors\":\"Bai Xue,&nbsp;Shuyu Wang,&nbsp;Tingting Wu,&nbsp;Lulu Wang,&nbsp;Xuejiao J. Gao,&nbsp;Mengyuan Cao,&nbsp;Ming Tang,&nbsp;Yuxin Wan,&nbsp;Xiyun Yan,&nbsp;Wei Jiang,&nbsp;Bing Jiang\",\"doi\":\"10.1126/sciadv.adu5571\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div >Retinal neovascularization diseases cause vision impairment due to abnormal blood vessel growth in the retina. Current treatments, including repeated intraocular anti–vascular endothelial growth factor injections, are invasive and often lead to discomfort and complicated hemorrhages. Here, we developed a noninvasive nanozyme eye drop capable of penetrating the fundus to eliminate reactive oxygen species (ROS) and thereby inhibit neovascularization. The nanozyme eye drops consist of liposomes formed by fluorinated and arginine–glycine–aspartic acid–modified phospholipids, which enhance the penetration of ocular barriers. The encapsulated superoxide dismutase–catalase cascade nanozyme within these liposomes allows for efficient ROS scavenging. In vitro and in vivo studies demonstrate that these nanozyme eye drops achieve deep retinal tissue penetration, alleviate oxidative stress, restore mitochondrial function, and suppress aberrant insulin-like growth factor binding protein 6 signaling, thereby inhibiting pathological neovascularization. Enhanced ocular bioavailability and minimal toxicity further underscore its promise as a safe and effective noninvasive treatment for retinal neovascularization diseases.</div>\",\"PeriodicalId\":21609,\"journal\":{\"name\":\"Science Advances\",\"volume\":\"11 38\",\"pages\":\"\"},\"PeriodicalIF\":12.5000,\"publicationDate\":\"2025-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.science.org/doi/reader/10.1126/sciadv.adu5571\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Science Advances\",\"FirstCategoryId\":\"103\",\"ListUrlMain\":\"https://www.science.org/doi/10.1126/sciadv.adu5571\",\"RegionNum\":1,\"RegionCategory\":\"综合性期刊\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science Advances","FirstCategoryId":"103","ListUrlMain":"https://www.science.org/doi/10.1126/sciadv.adu5571","RegionNum":1,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

摘要

视网膜新生血管疾病由于视网膜血管生长异常而造成视力损害。目前的治疗方法,包括反复眼内注射抗血管内皮生长因子,是侵入性的,经常导致不适和复杂的出血。在这里,我们开发了一种非侵入性纳米酶滴眼液,能够穿透眼底消除活性氧(ROS),从而抑制新生血管。纳米酶滴眼液由氟化磷脂和精氨酸-甘氨酸-天冬氨酸修饰磷脂形成的脂质体组成,增强了眼屏障的穿透性。这些脂质体内包裹的超氧化物歧化酶-过氧化氢酶级联纳米酶允许有效的活性氧清除。体外和体内研究表明,这些纳米酶滴眼液可深层渗透视网膜组织,减轻氧化应激,恢复线粒体功能,抑制异常的胰岛素样生长因子结合蛋白6信号,从而抑制病理性新生血管。增强的眼部生物利用度和最小的毒性进一步强调了其作为视网膜新生血管疾病安全有效的无创治疗方法的前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Nanozyme eye drops for retinal barrier penetration and vasculopathy repair

Nanozyme eye drops for retinal barrier penetration and vasculopathy repair
Retinal neovascularization diseases cause vision impairment due to abnormal blood vessel growth in the retina. Current treatments, including repeated intraocular anti–vascular endothelial growth factor injections, are invasive and often lead to discomfort and complicated hemorrhages. Here, we developed a noninvasive nanozyme eye drop capable of penetrating the fundus to eliminate reactive oxygen species (ROS) and thereby inhibit neovascularization. The nanozyme eye drops consist of liposomes formed by fluorinated and arginine–glycine–aspartic acid–modified phospholipids, which enhance the penetration of ocular barriers. The encapsulated superoxide dismutase–catalase cascade nanozyme within these liposomes allows for efficient ROS scavenging. In vitro and in vivo studies demonstrate that these nanozyme eye drops achieve deep retinal tissue penetration, alleviate oxidative stress, restore mitochondrial function, and suppress aberrant insulin-like growth factor binding protein 6 signaling, thereby inhibiting pathological neovascularization. Enhanced ocular bioavailability and minimal toxicity further underscore its promise as a safe and effective noninvasive treatment for retinal neovascularization diseases.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Science Advances
Science Advances 综合性期刊-综合性期刊
CiteScore
21.40
自引率
1.50%
发文量
1937
审稿时长
29 weeks
期刊介绍: Science Advances, an open-access journal by AAAS, publishes impactful research in diverse scientific areas. It aims for fair, fast, and expert peer review, providing freely accessible research to readers. Led by distinguished scientists, the journal supports AAAS's mission by extending Science magazine's capacity to identify and promote significant advances. Evolving digital publishing technologies play a crucial role in advancing AAAS's global mission for science communication and benefitting humankind.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信